ProKidney Corp.
PROKHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. With a market capitalization of $489.3M, it sits in small-cap territory. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes.
Market Cap
$489.3M
Beta
1.68
P/E (TTM)
—
P/E (Fwd)
-2.81
EPS (TTM)
$-0.53
EPS (Fwd)
$-0.58
ROE
-49.4%
ROA
-30.1%
Cash
$224.9M
Total Debt
$3.8M
Free CF
-$78.6M
52W Change
-48.6%
Annual Financials
Cash vs Debt
ProKidney Corp. holds $224.9M in cash against $3.8M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$78.6M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -49.4% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
A beta of 1.68 means PROK is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. With cash comfortably exceeding debt, PROK has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing PROK's risk profile alongside its fundamentals and technical indicators provides a more complete picture.